Olivier Vandenplas1, Julien Godet2, Laura Hurdubaea3, Catherine Rifflart4, Hille Suojalehto5, Jolanta Walusiak-Skorupa6, Xavier Munoz7, Joaquin Sastre8, Pavlina Klusackova9, Vicky Moore10, Rolf Merget11, Donatella Talini12, Jorunn Kirkeleit13, Paola Mason14, Ilenia Folletti15, Paul Cullinan16, Gianna Moscato17, Santiago Quirce18, Jennifer Hoyle19, David Sherson20, Paula Kauppi21, Alexandra Preisser22, Nicolas Meyer2, Frédéric de Blay3. 1. Department of Chest Medicine, Centre Hospitalier Universitaire UCL Namur, Université Catholique de Louvain, Yvoir, Belgium. Electronic address: olivier.vandenplas@uclouvain.be. 2. Groupe Méthode Recherche Clinique, Pôle de Santé Publique, Strasbourg University, Strasbourg, France. 3. Division of Asthma and Allergy, Department of Chest Diseases, University Hospital of Strasbourg and Fédération de Médecine translationnelle, Strasbourg University, Strasbourg, France. 4. Department of Chest Medicine, Centre Hospitalier Universitaire UCL Namur, Université Catholique de Louvain, Yvoir, Belgium. 5. Occcupational Medicine, Finnish Institute of Occupational Health, Helsinki, Finland. 6. Department of Occupational Diseases and Environmental Health, Nofer Institute of Occupational Medicine, Lodz, Poland. 7. Servei Pneumologia, Hospital Vall d'Hebron, Universitat Autonoma de Barcelona and CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain. 8. Department of Allergy, Fundacion Jimenez Dıaz and CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain. 9. Department of Occupational Medicine, 1st Faculty of Medicine, Charles University, Prague, Czech Republic. 10. Occupational Lung Disease Unit, Birmingham Heartlands Hospital, Birmingham, United Kingdom. 11. Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Ruhr University, Bochum, Germany. 12. Cardio-Thoracic and Vascular Department, University of Pisa, Pisa, Italy. 13. Department of Occupational Medicine, Haukeland University Hospital, Bergen, Norway. 14. Unit of Occupational Medicine and Public Health, University of Padova, Padova, Italy. 15. Department of Medicine, Section of Occupational Medicine, Respiratory Diseases and Occupational and Environmental Toxicology, University of Perugia, Perugia, Italy. 16. Department of Occupational and Environmental Medicine, Royal Brompton Hospital and Imperial College (NHLI), Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom. 17. Department of Public Health, Experimental and Forensic Medicine, University of Pavia, and Allergy and Immunology Unit, Istituti Clinici Scientifici Maugeri, IRCCS, Pavia, Italy. 18. Department of Allergy, Hospital La Paz Institute for Health Research (IdiPAZ) and CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain. 19. Department of Respiratory Medicine, North Manchester General Hospital, Manchester, United Kingdom. 20. Department of Pulmonary Medicine and Occupational Medicine, Odense University Hospital, Odense, Denmark. 21. Department of Allergy, Skin and Allergy Hospital, Helsinki University Central Hospital, Helsinki, Finland. 22. Institute for Occupational and Maritime Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Abstract
BACKGROUND: Although sensitizer-induced occupational asthma (OA) accounts for an appreciable fraction of adult asthma, the severity of OA has received little attention. OBJECTIVE: The aim of this study was to characterize the burden and determinants of severe OA in a large multicenter cohort of subjects with OA. METHODS: This retrospective study included 997 subjects with OA ascertained by a positive specific inhalation challenge completed in 20 tertiary centers in 11 European countries during the period 2006 to 2015. Severe asthma was defined by a high level of treatment and any 1 of the following criteria: (1) daily need for a reliever medication, (2) 2 or more severe exacerbations in the previous year, or (3) airflow obstruction. RESULTS: Overall, 162 (16.2%; 95% CI, 14.0%-18.7%) subjects were classified as having severe OA. Multivariable logistic regression analysis revealed that severe OA was associated with persistent (vs reduced) exposure to the causal agent at work (odds ratio [OR], 2.78; 95% CI, 1.50-5.60); a longer duration of the disease (OR, 1.04; 95% CI, 1.00-1.07); a low level of education (OR, 2.69; 95% CI, 1.73-4.18); childhood asthma (OR, 2.92; 95% CI, 1.13-7.36); and sputum production (OR, 2.86; 95% CI, 1.87-4.38). In subjects removed from exposure, severe OA was associated only with sputum production (OR, 3.68; 95% CI, 1.87-7.40); a low education level (OR, 3.41; 95% CI, 1.72-6.80); and obesity (OR, 1.98; 95% CI, 0.97-3.97). CONCLUSIONS: This study indicates that a substantial proportion of subjects with OA experience severe asthma and identifies potentially modifiable risk factors for severe OA that should be targeted to reduce the adverse impacts of the disease.
BACKGROUND: Although sensitizer-induced occupational asthma (OA) accounts for an appreciable fraction of adult asthma, the severity of OA has received little attention. OBJECTIVE: The aim of this study was to characterize the burden and determinants of severe OA in a large multicenter cohort of subjects with OA. METHODS: This retrospective study included 997 subjects with OA ascertained by a positive specific inhalation challenge completed in 20 tertiary centers in 11 European countries during the period 2006 to 2015. Severe asthma was defined by a high level of treatment and any 1 of the following criteria: (1) daily need for a reliever medication, (2) 2 or more severe exacerbations in the previous year, or (3) airflow obstruction. RESULTS: Overall, 162 (16.2%; 95% CI, 14.0%-18.7%) subjects were classified as having severe OA. Multivariable logistic regression analysis revealed that severe OA was associated with persistent (vs reduced) exposure to the causal agent at work (odds ratio [OR], 2.78; 95% CI, 1.50-5.60); a longer duration of the disease (OR, 1.04; 95% CI, 1.00-1.07); a low level of education (OR, 2.69; 95% CI, 1.73-4.18); childhood asthma (OR, 2.92; 95% CI, 1.13-7.36); and sputum production (OR, 2.86; 95% CI, 1.87-4.38). In subjects removed from exposure, severe OA was associated only with sputum production (OR, 3.68; 95% CI, 1.87-7.40); a low education level (OR, 3.41; 95% CI, 1.72-6.80); and obesity (OR, 1.98; 95% CI, 0.97-3.97). CONCLUSIONS: This study indicates that a substantial proportion of subjects with OA experience severe asthma and identifies potentially modifiable risk factors for severe OA that should be targeted to reduce the adverse impacts of the disease.
Authors: Lavinia Clara Del Roio; Rafael Futoshi Mizutani; Regina Carvalho Pinto; Mário Terra-Filho; Ubiratan Paula Santos Journal: J Bras Pneumol Date: 2021-08-11 Impact factor: 2.624
Authors: Woori Jo; Kwang Won Seo; Hwa Sik Jung; Chui Yong Park; Byung Ju Kang; Hyeon Hui Kang; Seung Won Ra; Yangjin Jegal; Jong Joon Ahn; Soon Eun Park; Moon Sik Jung; Ju Ik Park; Eun Ji Park; Chang Sun Sim; Tae Bum Kim; Taehoon Lee Journal: Allergy Asthma Immunol Res Date: 2021-03 Impact factor: 5.764
Authors: Regina Maria de Carvalho-Pinto; José Eduardo Delfini Cançado; Marcia Margaret Menezes Pizzichini; Jussara Fiterman; Adalberto Sperb Rubin; Alcindo Cerci Neto; Álvaro Augusto Cruz; Ana Luisa Godoy Fernandes; Ana Maria Silva Araujo; Daniela Cavalet Blanco; Gediel Cordeiro Junior; Lilian Serrasqueiro Ballini Caetano; Marcelo Fouad Rabahi; Marcelo Bezerra de Menezes; Maria Alenita de Oliveira; Marina Andrade Lima; Paulo Márcio Pitrez Journal: J Bras Pneumol Date: 2021-12-15 Impact factor: 2.624